Raynaud's phenomenon possibly induced by a compund drug of tegafur and uracil.
We describe a 50-year-old woman who noted acral hyperpigmentation, sclerodactyly and Raynaud's phenomenon with 1:160 of antinuclear antibody titer after treatment with a compound drug with tegafur and uracil. Histological findings of the finger and palm included hyperkeratosis, vacuolar degeneration of basal cells, thickened collagen fibers in the dermis, and dilatation of capillary vessels, perivascular mononuclear cell infiltration and melanophages in the upper dermis. IgG, IgA, IgM, C3 and C1q were not deposited in the skin by direct immunofluorescence study. After cessation of the drug, Raynaud's phenomenon and hyperpigmentation disappeared within 1 month and 4 months, respectively, and antinuclear antibody turned negative within 4 months. These observations suggest that tegafur may have caused not only hyperpigmentation in the palms and soles, but also sclerodactyly and Raynaud's phenomenon in the present case.
Seishima
M
M
Department of Dermatology, Ogaki Municipal Hospital, Minaminokawa-cho 4-86, Ogaki City, 503-8502, Japan. seimarik@gumail.cc.gifu-u.ac.jp.
Izumi
T
T
Kanoh
H
H
D000974:Antibodies, Antinuclear / Q000032:analysis; D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008875:Middle Aged; D011928:Raynaud Disease / Q000139:chemically induced* / Q000276:immunology / Q000473:pathology; D012595:Scleroderma, Systemic / Q000139:chemically induced / Q000276:immunology / Q000473:pathology; D012867:Skin / Q000098:blood supply; D005641:Tegafur / Q000009:adverse effects*; D014498:Uracil / Q000009:adverse effects*
D000974:Antibodies, Antinuclear; D000964:Antimetabolites, Antineoplastic; D005641:Tegafur; D014498:Uracil